Delve Health helps biotechs run efficient, high-quality decentralized and hybrid studies without massive internal teams or complex multi-vendor setups. Unified data capture, real-time oversight, and human support keep execution on track from first patient to readout.
Less overhead · Faster timelines · More defensible evidence.
Your Study Needs Speed — Not Complexity
Biotechs need to move quickly, operate lean, and build evidence that stands up to regulatory scrutiny. Delve Health brings together eCOA, wearables, diaries, patient engagement, and concierge support into one platform purpose-built for smaller teams.
Fit-for-purpose eCOA + wearable platform
Reduced operational burden for small teams
Adaptive workflows for early-phase trials
Faster deployment with minimal IT overhead
Built for Emerging Biotechs
Move fast without sacrificing data quality. Delve gives lean teams a unified platform for eCOA, wearables, and compliance—backed by real humans when execution gets messy.
Fast Deployment
Launch eCOA and wearables in weeks, not months.
Fit-for-Purpose Endpoints
Validated digital biomarkers aligned with regulatory expectations.
Human Concierge
Multilingual outreach keeps participants engaged and compliant.
Lean Team Ready
Automated oversight plus human support reduces operational load.
eCOA + Wearables in One Place
Early-phase and exploratory studies rely on accurate, continuous data. Delve provides a single, validated infrastructure for collecting both subjective and objective endpoints.
Wearable endpoints aligned with FDA/EMA frameworks
ePRO + symptom scoring with audit trails
Real-time device and diary compliance monitoring
Objective–subjective signal correlation
Stronger Early Data With Human Support
Early-phase studies struggle with variability. When a patient gets stuck, a device misbehaves, or a diary is missed — our concierge intervenes in real time to protect data quality.
Daily oversight of patient signals
Proactive sync + battery troubleshooting
Visit reminders and adherence coaching
Significant reduction in missingness
Powering Evidence for Emerging Biotechs
Early-Phase Digital Endpoint Study
Objective signals validated against gold-standard methods.
Decentralized Rare Disease Trial
92% ePRO completion across a hard-to-reach population.
Exploratory Biomarker Program
35% faster data readouts with real-time dashboarding.
92%
ePRO Completion
87%
Patient Retention
95%
Wearable Compliance
30%
Faster Interim Readouts
Move Your Science Forward — Faster.
One platform. Validated endpoints. Human retention. Everything a biotech needs to scale evidence.